Model-guided non-whitening endpoint for 755-nm picosecond laser treatment of acquired bilateral nevus of Ota-like macules (ABNOM) in pigmented skin: A randomized split-face trial.
Xue Wang, Xiaojin Wu, Xianglei Wu et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized split-face trial evaluated the efficacy of a model-guided non-whitening endpoint versus a conventional whitening endpoint in treating acquired bilateral nevus of Ota-like macules (ABNOM) in 30 Asian patients with Fitzpatrick skin types III-V. Both methods achieved high clearance rates, but the non-whitening approach resulted in significantly lower post-inflammatory hyperpigmentation (PIH) rates (4.8% vs 22.6%).
Key findings
- Both endpoints achieved high clearance rates (Global Aesthetic Improvement Scale >3.85/4).
- The whitening endpoint resulted in 22.6% PIH compared to 4.8% for the non-whitening endpoint (P < .05).
- Scabbing occurred in 61.9% of the whitening group versus 9.5% in the non-whitening group (P < .05).
- 68% of patients preferred the non-whitening endpoint.
Why it matters
The findings suggest that using a model-guided non-whitening endpoint may reduce the risk of post-inflammatory hyperpigmentation and scabbing in laser treatments for pigmented skin, potentially leading to better patient outcomes and satisfaction.
What to keep in mind
Single-center study with limited inclusion of Fitzpatrick skin types III-V.